Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) EPS (Weighted Average and Diluted) (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$309.43 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) fell 59.57% year-over-year to -$309.43, compared with a TTM value of -$501.82 through Sep 2025, down 109.96%, and an annual FY2024 reading of -$366.33, down 50082.19% over the prior year.
  • EPS (Weighted Average and Diluted) was -$309.43 for Q3 2025 at Ovid Therapeutics, down from -$64.73 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $117.61 in Q2 2024 and bottomed at -$309.43 in Q3 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$38.97, with a median of -$0.2 recorded in 2023.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 65438.89% in 2024, while the deepest fall reached 121100.0% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.38 in 2021, then soared by 57.89% to -$0.16 in 2022, then fell by 25.0% to -$0.2 in 2023, then plummeted by 63660.0% to -$127.52 in 2024, then tumbled by 142.65% to -$309.43 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for OVID at -$309.43 in Q3 2025, -$64.73 in Q2 2025, and -$0.14 in Q1 2025.